These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 1739419

  • 1. Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species.
    Yu PH, Zuo DM.
    Biochem Pharmacol; 1992 Jan 22; 43(2):307-12. PubMed ID: 1739419
    [Abstract] [Full Text] [Related]

  • 2. Characterization of human serum and umbilical artery semicarbazide-sensitive amine oxidase (SSAO). Species heterogeneity and stereoisomeric specificity.
    Yu PH, Zuo DM, Davis BA.
    Biochem Pharmacol; 1994 Mar 15; 47(6):1055-9. PubMed ID: 8147904
    [Abstract] [Full Text] [Related]

  • 3. Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential.
    Palfreyman MG, McDonald IA, Bey P, Danzin C, Zreika M, Cremer G.
    J Neural Transm Suppl; 1994 Mar 15; 41():407-14. PubMed ID: 7931257
    [Abstract] [Full Text] [Related]

  • 4. Assessment of the deamination of aminoacetone, an endogenous substrate for semicarbazide-sensitive amine oxidase.
    Deng Y, Yu PH.
    Anal Biochem; 1999 May 15; 270(1):97-102. PubMed ID: 10328770
    [Abstract] [Full Text] [Related]

  • 5. Inhibitor sensitivity of human serum and vascular semicarbazide-sensitive amine oxidases.
    Mészáros Z, Csányi A, Vallus G, Szombathy T, Karádi I, Magyar K.
    Neurobiology (Bp); 2000 May 15; 8(2):215-23. PubMed ID: 11061216
    [Abstract] [Full Text] [Related]

  • 6. In-vivo effects of (E)-2-(3',4'-dimethoxyphenyl)-3-fluoroallylamine (MDL 72145) on amine oxidase activities in the rat. Selective inhibition of semicarbazide-sensitive amine oxidase in vascular and brown adipose tissues.
    Elliott J, Callingham BA, Barrand MA.
    J Pharm Pharmacol; 1989 Jan 15; 41(1):37-41. PubMed ID: 2565962
    [Abstract] [Full Text] [Related]

  • 7. An allylamine derivative (MDL 72145) with potent irreversible inhibitory actions on rat aorta semicarbazide-sensitive amine oxidase.
    Lyles GA, Fitzpatrick CM.
    J Pharm Pharmacol; 1985 May 15; 37(5):329-35. PubMed ID: 2862241
    [Abstract] [Full Text] [Related]

  • 8. MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease.
    Zreika M, Fozard JR, Dudley MW, Bey P, McDonald IA, Palfreyman MG.
    J Neural Transm Park Dis Dement Sect; 1989 May 15; 1(4):243-54. PubMed ID: 2597310
    [Abstract] [Full Text] [Related]

  • 9. Studies of monoamine oxidase and semicarbazide-sensitive amine oxidase. I. Inhibition by a selective monoamine oxidase-B inhibitor, MD 780236.
    Kinemuchi H, Morikawa F, Ueda T, Arai Y.
    Jpn J Pharmacol; 1986 Jun 15; 41(2):183-9. PubMed ID: 3747265
    [Abstract] [Full Text] [Related]

  • 10. Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
    Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A.
    Prog Neuropsychopharmacol Biol Psychiatry; 1988 Jun 15; 12(6):967-87. PubMed ID: 3266532
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Inhibition of rat aorta semicarbazide-sensitive amine oxidase by 2-phenyl-3-haloallylamines and related compounds.
    Lyles GA, Marshall CM, McDonald IA, Bey P, Palfreyman MG.
    Biochem Pharmacol; 1987 Sep 01; 36(17):2847-53. PubMed ID: 3632710
    [Abstract] [Full Text] [Related]

  • 13. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
    Palfreyman MG, McDonald IA, Zreika M, Cremer G, Haegele KD, Bey P.
    J Neural Transm Suppl; 1993 Sep 01; 40():101-11. PubMed ID: 8294896
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of semicarbazide-sensitive amine oxidase by monoamine oxidase B inhibitors from the oxazolidinone series.
    Dostert P, Guffroy C, Strolin Benedetti M, Boucher T.
    J Pharm Pharmacol; 1984 Nov 01; 36(11):782-5. PubMed ID: 6150988
    [Abstract] [Full Text] [Related]

  • 15. Semicarbazide-sensitive amine oxidase from the smooth muscles of dog aorta and trachea: activation by the MAO-A inhibitor clorgyline.
    Yu PH, Fang CY, Yang CM.
    J Pharm Pharmacol; 1992 Dec 01; 44(12):981-5. PubMed ID: 1361563
    [Abstract] [Full Text] [Related]

  • 16. Deamination of methylamine by semicarbazide-sensitive amine oxidase in human umbilical artery and rat aorta.
    Precious E, Gunn CE, Lyles GA.
    Biochem Pharmacol; 1988 Feb 15; 37(4):707-13. PubMed ID: 3342102
    [Abstract] [Full Text] [Related]

  • 17. Glucose handling in streptozotocin-induced diabetic rats is improved by tyramine but not by the amine oxidase inhibitor semicarbazide.
    Visentin V, Bour S, Boucher J, Prévot D, Valet P, Ordener C, Parini A, Carpéné C.
    Eur J Pharmacol; 2005 Oct 17; 522(1-3):139-46. PubMed ID: 16202994
    [Abstract] [Full Text] [Related]

  • 18. Reduction of fat deposition by combined inhibition of monoamine oxidases and semicarbazide-sensitive amine oxidases in obese Zucker rats.
    Carpéné C, Iffiú-Soltesz Z, Bour S, Prévot D, Valet P.
    Pharmacol Res; 2007 Dec 17; 56(6):522-30. PubMed ID: 17977742
    [Abstract] [Full Text] [Related]

  • 19. Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications.
    Yu PH, Zuo DM.
    Diabetologia; 1997 Nov 17; 40(11):1243-50. PubMed ID: 9389414
    [Abstract] [Full Text] [Related]

  • 20. Simultaneous determination of formaldehyde and methylglyoxal in urine: involvement of semicarbazide-sensitive amine oxidase-mediated deamination in diabetic complications.
    Deng Y, Yu PH.
    J Chromatogr Sci; 1999 Sep 17; 37(9):317-22. PubMed ID: 10497785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.